查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1806134

生物防禦市場按產品類型、病原體類型、技術、應用、最終用戶和分銷管道分類—2025-2030 年全球預測

Biodefense Market by Product Type, Pathogen Type, Technology, Application, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計生物防禦市場規模到 2024 年將達到 203.3 億美元，到 2025 年將達到 227.1 億美元，到 2030 年將達到 387.7 億美元，複合年成長率為 11.35%。

主要市場統計數據
基準年2024年 203.3億美元
預計2025年 227.1億美元
預測年份 2030 387.7億美元
複合年成長率（%） 11.35%

在這個生物威脅以前所未有的速度和隱蔽性出現和傳播的時代，全面了解生物防禦生態系統比以往任何時候都更重要。全球社會面臨自然爆發、意外洩漏以及病原體的蓄意惡意使用等風險，迫切需要製定強力的檢測、預防和應對策略。這項背景促使政府、產業和科學研究相關人員加快對下一代技術和協作框架的投資，以彌補生物防禦價值鏈各個環節的漏洞。

本執行摘要提煉了重新定義防範措施領域最突出的發展，包括產品創新、政策轉變、供應鏈韌性和策略夥伴關係。透過對轉型動態、貿易政策影響、細分領域洞察和區域差異進行結構化分析，本摘要提供了決策者如何針對新興生物威脅情境協調資源和能力的整體觀點。

本簡報透過追溯技術進步與監管調整之間的相互關係，為領導者提供了清晰的行動藍圖。它也強調了公私協同和國際合作將如何塑造未來幾年的機制。由此，它為隨後的詳細策略建議、調查方法揭露和結論奠定了基礎，使各組織能夠在快速變化的風險環境中加強防範，提升韌性。

確定重新定義生物防禦準備能力和整個價值鏈產業協作的關鍵變革動力

生物防禦領域正被一波突破性的技術創新和新穎的協作模式再形成，這些創新和模式正在重新定義威脅偵測和回應的可能性。合成生物學和基因編輯技術的進步提供了更靈敏的診斷平台，而人工智慧和機器學習則最佳化了預測分析，並加速了新興病原體的識別。這些技術突破並非孤立存在；它們正被整合到物聯網和雲端基礎架構中，建構一個無縫的即時監控和快速情境察覺網路。

全面評估2025年美國關稅調整對生物防禦採購和供應鏈的影響。

美國宣布的2025年新關稅將對生物防禦供應鏈、籌資策略和國內製造業獎勵產生深遠影響。關鍵原料、診斷設備和專用試劑的進口關稅將上調，直接影響國際供應商和下游整合商的成本結構。這些貿易政策變化迫使企業重新評估供應商關係、成本談判和庫存管理實踐，以減輕關稅上調和物流延誤的影響。

揭示產品類型、病原體、類別、技術、應用、最終用戶和分銷管道的關鍵細分觀點

生物防禦市場從多方面進行分析，包括產品類型、病原體類別、技術平台、應用領域、最終用戶概況和分銷模式。在產品頻譜內，淨化解決方案分為表面消毒劑和個人防護設備，提供防止污染的第一道防線。檢測平台涵蓋生物感測器陣列和病原體檢測系統，每種平台均針對快速、現場可部署的篩檢或高通量實驗室診斷量身定做。治療藥物包括抗病毒和單株抗體療法、小分子介入措施以及為精準標靶化設計的生物製藥。疫苗製劑包括炭疽菌、肉毒桿菌和天花疫苗，每種疫苗均針對特定的生物威脅情境和免疫學特徵量身打造。

重點介紹美洲、歐洲、中東和非洲以及亞太地區的主要區域差異和戰略生物防禦重點

受威脅認知、預算分配和基礎設施能力差異的影響，生物防禦領域的區域動態差異巨大。在美洲，現有的國防計畫和大量的聯邦研究津貼支撐著一個由國家實驗室和國內製造商組成的強大網路。該地區在疫苗開發、治療研究和診斷平台創新方面的主導地位得益於學術中心和商業實體之間的深度整合。具有全球影響力的監管機構的存在進一步加速了關鍵應對措施的核准和國際部署。

創新和合作夥伴關係塑造競爭格​​局；企業策略舉措

領先的生物防禦產業公司以其多元化的創新、夥伴關係和商業化方法而聞名。大型製藥企業正在利用其先進的生物加工能力和良好的監管記錄，增加對下一代疫苗平台、抗體工程和抗病毒藥物開發的關注。這些成熟的公司正在與規模較小的專業技術供應商建立策略聯盟，以加快開發週期並擴大其全球影響力。

加強生物防禦生態系統的彈性、敏捷性和聯合準備的可行策略建議

為了加強生物防禦準備並推動持續創新，各組織機構應採取多管齊下的策略，重點關注早期檢測、供應鏈穩健性和協作情報。首先，投資先進的診斷平台，例如高通量測序和人工智慧驅動的生物感測器網路，可以更快地識別威脅並更準確地追蹤流行病學。將這些技術嵌入分散式檢查中心，可以進一步擴大偵測覆蓋範圍並減少回應延遲。

收集數據以洞察生物防禦市場。採用結合專家諮詢和嚴格分析架構的深入調查方法。

我們的分析基於一個全面的研究框架，該框架融合了行業專家的一手資料研究和嚴謹的二手資料收集。我們最初的二手資料研究包括系統性地回顧同行評審的出版物、政府白皮書、監管文件和專利資料庫，以識別基本趨勢和新興技術。這些競爭考察與詳細的公司概況和財務揭露相輔相成，從而揭示當前的競爭動態和投資流向。

關於未來發展軌蹟的總結：優先考慮全球生物防禦領域的準備和新創新

隨著全球威脅情勢的不斷演變，制定一個協調一致、靈活的生物防禦策略的需求比以往任何時候都更加迫切。技術進步、貿易政策的轉變以及區域優先事項的動態變化，要求我們採取一種能夠連接檢測、預防和回應的綜合方法。能夠成功將先進的診斷平台與彈性供應鏈模型和靈活監管途徑結合的組織，將最有能力應對已知和新興的生物風險。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 擴展人工智慧驅動的病原體檢測平台，實現即時生物防禦監測
  • 合成生物投資激增，疫苗開發平臺加速
  • 引進現場移動實驗室，提升現場應變能力
  • 將基因組監測網路納入國家預警系統
  • 加強國防機構與生物製藥公司在對策研發方面的合作
  • 過渡到基於 CRISPR 的診斷檢測，以實現對新出現的威脅的即時檢測
  • 引入雲端基礎的生物資訊平台，用於分析和共用全球病原體威脅
  • 政府主導的資金用於擴大高防護設施的容量
  • 新興的綜合供應鏈彈性策略，以確保關鍵醫療用品的安全
  • 監管協調努力，簡化新對策的緊急使用核准流程

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章 生物防禦市場（依產品類型）

  • 淨化產品
    • 消毒劑
    • 個人防護設備
  • 檢測裝置
    • 生物感測器
    • 病原體檢測系統
  • 治療藥物
    • 抗病毒治療
    • 單株抗體
  • 疫苗
    • 炭疽菌疫苗
    • 肉毒桿菌疫苗
    • 天花疫苗

9. 生物防禦市場（依病原體類型）

  • 細菌因素
  • 毒素
  • 病毒因子

第 10 章。生物防禦市場（按技術）

  • 免疫檢測
  • 質譜法
  • 次世代定序
  • 聚合酵素鏈鎖反應

第 11 章 生物防禦市場（依應用）

  • 檢測與診斷
  • 預防
  • 治療

第 12 章 生物防禦市場（依最終使用者）

  • 學術研究機構
  • 政府和國防機構
  • 醫院和診所
  • 製藥和生物技術公司

第 13 章。生物防禦市場（按分銷管道）

  • 線下通路
  • 線上管道

第 14 章：美洲生物防禦市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15.歐洲、中東和非洲生物防禦市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

第 16 章：亞太生物防禦市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Emergent BioSolutions Inc.
    • Siga Technologies, Inc.
    • Xoma Corporation
    • Altimmune, Inc.
    • Dynavax Technologies Corporation
    • Elusys Therapeutics, Inc.
    • Ichor Medical Systems
    • DynPort Vaccine Company LLC
    • Luminex Corporation
    • Cleveland Biolabs Inc.
    • Bavarian Nordic A/S
    • Alnylam Pharmaceuticals, Inc.
    • QIAGEN NV
    • Ecolab Inc.
    • Abbott Laboratories
    • Bio-Rad Laboratories
    • Nova Biomedical Corporation
    • Siemens Healthcare
    • Strados Labs
    • Thermo Fisher Scientific
    • Biofourmis Singapore Pte. Ltd.
    • SD BIOSENSOR
    • Lucentix SA

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-434CCDA050CE

The Biodefense Market was valued at USD 20.33 billion in 2024 and is projected to grow to USD 22.71 billion in 2025, with a CAGR of 11.35%, reaching USD 38.77 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 20.33 billion
Estimated Year [2025] USD 22.71 billion
Forecast Year [2030] USD 38.77 billion
CAGR (%) 11.35%

In an era where biological threats can emerge and propagate with unprecedented speed and stealth, a comprehensive understanding of the biodefense ecosystem is more critical than ever. The global community faces a convergence of natural outbreaks, accidental releases, and deliberate malicious use of pathogens, creating a pressing need for robust detection, prevention, and response strategies. Against this backdrop, stakeholders across government, industry, and research institutions are accelerating investments in next-generation technologies and collaborative frameworks to shore up vulnerabilities at every point along the biodefense value chain.

This executive summary distills the most salient developments across product innovation, policy shifts, supply chain resilience, and strategic partnerships that are redefining preparedness. Through a structured analysis of transformative dynamics, trade policy implications, segment-level insights, and regional variations, the content provides a holistic perspective on how decision-makers can align resources and capabilities to emerging biothreat scenarios.

By tracing the interplay between technological advances and regulatory adaptations, this overview equips leaders with a clear roadmap for action. It highlights the mechanisms through which public-private synergies and international cooperation will shape the coming years. In doing so, it lays the groundwork for the detailed strategic recommendations, methodological disclosure, and concluding perspectives that follow, empowering organizations to bolster readiness and foster resilience in a rapidly evolving risk environment.

Identifying Major Transformative Dynamics Redefining Biodefense Readiness Capabilities and Industry Collaboration Across the Value Chain

The biodefense arena is being reshaped by a wave of groundbreaking innovations and novel collaborative models that collectively redefine what is possible in threat detection and response. Advances in synthetic biology and gene editing are delivering more sensitive diagnostic platforms, while artificial intelligence and machine learning optimize predictive analytics and accelerate the identification of emerging pathogens. These technological breakthroughs are not isolated; they are being integrated into expansive Internet of Things networks and cloud-based architectures, creating a seamless fabric of real-time surveillance and rapid situational awareness.

Equally significant has been the emergence of public-private consortiums and cross-sector partnerships designed to mobilize resources and expertise with unprecedented speed. By pooling laboratory capabilities from academic centers, defense programs, and commercial innovators, these collaborations are streamlining the path from discovery to deployment. At the same time, regulatory bodies are modernizing approval pathways and issuing adaptive guidance to ensure that critical countermeasures can be fielded without undue delay or compromise of safety standards.

A parallel shift has been underway in supply chain management, where resilience has taken precedence over cost-minimization. Organizations are investing in redundant manufacturing nodes and diversifying sourcing strategies for key reagents, protective equipment, and biologics. This emphasis on robustness extends into logistics, with specialized cold-chain networks and expedited distribution channels designed to maintain readiness under stress conditions.

Together, these transformative shifts form an integrated blueprint for a more agile and responsive biodefense ecosystem. By understanding these dynamics, stakeholders can better position themselves to harness the full potential of emerging technologies, regulatory flexibilities, and collaborative infrastructures.

Assessing the Comprehensive Implications of United States Tariff Adjustments Set to Take Effect in 2025 on Biodefense Procurements and Supply Chains

New tariff measures announced in the United States for 2025 will have far-reaching effects on the biodefense supply chain, procurement strategies, and domestic manufacturing incentives. Import duties on critical raw materials, diagnostic instruments, and specialized reagents are set to increase, directly affecting the cost structures of international suppliers and downstream integrators. This shift in trade policy is prompting organizations to revisit supplier relationships, cost negotiations, and inventory management practices to mitigate exposure to higher duties and logistical delays.

As a result, many stakeholders are accelerating plans to establish or expand onshore production facilities. Domestic manufacturing of detection devices, therapeutic antibodies, and vaccine adjuvants is being pursued not only to contain costs but also to enhance strategic autonomy in the face of cross-border restrictions. Policymakers are reinforcing these efforts by offering incentives such as tax credits, accelerated approval processes for localized production methods, and targeted research grants to underpin near-term scale-up projects.

Procurement agencies are also adapting their contracting frameworks to incorporate total-cost-of-ownership models that factor in tariff impacts, currency fluctuations, and potential supply disruptions. This holistic approach is enabling clearer decision criteria, balancing unit pricing with considerations for delivery lead times, quality assurance, and long-term regulatory compliance.

In the face of these policy shifts, stakeholders who proactively align manufacturing footprints, diversify import sources, and engage in strategic partnerships will be best positioned to sustain resilience. By leveraging domestic production incentives and adopting more integrated procurement strategies, organizations can navigate tariff pressures while safeguarding mission-critical capabilities.

Unveiling Key Segmentation Perspectives Spanning Product Types Pathogen Categories Technologies Applications End Users and Distribution Channels

The biodefense market is dissected through a multifaceted lens that encompasses product types, pathogen categories, technological platforms, application areas, end-user profiles, and distribution formats. Within the product spectrum, decontamination solutions are split between surface disinfectants and personal protective equipment, offering frontline defense against contamination. Detection platforms extend across biosensor arrays and pathogen detection systems, each calibrated for rapid, field-deployable screening or high-throughput laboratory diagnostics. Therapeutic offerings span antiviral therapies alongside monoclonal antibodies, reflecting both small molecule interventions and biologics designed for precision targeting. Vaccine formulations include those for anthrax, botulism, and smallpox, each tailored to specific biothreat scenarios and immunological profiles.

When viewed through the lens of pathogen type, the analysis covers bacterial agents, toxins, and viral threats, ensuring that countermeasure development is aligned with the biological characteristics and transmission pathways of diverse organisms. The technology domain explores immunoassays, mass spectrometry, next generation sequencing, and polymerase chain reaction modalities, illustrating how each platform contributes unique strengths in terms of sensitivity, specificity, and throughput.

Application analysis delineates detection and diagnostics from preventive strategies and therapeutic interventions, underscoring the continuum from early warning to clinical management. End-user segmentation highlights the differing operational needs of entities such as academic and research institutes, government and defense agencies, hospitals and clinics, and pharmaceutical and biotechnology companies. Finally, distribution channel differentiation between offline and online mechanisms sheds light on procurement preferences, logistical considerations, and the evolving role of e-commerce in life science supplies.

Through this comprehensive segmentation framework, stakeholders can pinpoint the precise intersections of need and capability, optimizing resource allocation and innovation focus within the broader biodefense ecosystem.

Highlighting Vital Regional Differentials and Strategic Biodefense Priorities Across the Americas Europe Middle East Africa and Asia Pacific

Regional dynamics in the biodefense arena diverge significantly, driven by distinct threat perceptions, budgetary allocations, and infrastructural capabilities. In the Americas, well-established defense programs and substantial federal research grants underpin a robust network of national laboratories and domestic manufacturers. This region's leading role in vaccine development, therapeutic research, and diagnostic platform innovation benefits from deep integration between academic centers and commercial entities. The presence of regulatory agencies with global influence further accelerates the approval and international deployment of critical countermeasures.

Europe, the Middle East, and Africa present a mosaic of regulatory frameworks and threat landscapes. European Union member states emphasize harmonized standards and cross-border data sharing, facilitating joint procurement and collaborative R&D initiatives. Meanwhile, Middle Eastern and African nations prioritize capacity building in public health infrastructure and border surveillance to address emerging zoonotic risks. Across this expanse, strategic partnerships with regional hubs are fostering knowledge transfer, training programs, and the establishment of rapid response teams equipped for both natural outbreak and bioterror scenarios.

The Asia-Pacific region has emerged as a focal point for manufacturing scale-up and technology transfer. Several economies in this zone are rapidly expanding vaccine production capabilities and investing in advanced sequencing and diagnostic platforms. Robust government funding, coupled with public health modernization drives, is creating a fertile environment for local innovators to partner with global defense contractors. As a result, supply chains are becoming more diversified, reducing reliance on traditional western hubs and strengthening regional resilience against disruption.

These regional insights underscore the necessity of tailoring strategies to local contexts. By recognizing the specific strengths and constraints of each zone, stakeholders can orchestrate more effective collaborations, optimize resource allocation, and ensure that critical biodefense capabilities are deployed where they are needed most.

Key Corporate Strategic Initiatives Technological Innovations and Collaborative Partnerships Shaping the Competitive Biodefense Landscape

Leading organizations within the biodefense landscape are distinguished by their multifaceted approaches to innovation, partnership, and commercialization. Large pharmaceutical and biotechnology firms have intensified their focus on next-generation vaccine platforms, antibody engineering, and antiviral drug development, leveraging advanced bioprocessing capabilities and robust regulatory track records. These incumbents have entered into strategic alliances with smaller specialized technology providers to accelerate development cycles and expand global reach.

In the diagnostic arena, companies specializing in biosensors and rapid pathogen detection systems are pioneering point-of-care solutions that combine miniaturized hardware with artificial intelligence-driven analytics. Their success in securing government contracts and defense grants underscores the shifting emphasis toward distributed surveillance models. At the same time, developers of decontamination products are integrating novel antimicrobial chemistries and self-sanitizing surface materials into personal protective equipment, addressing both health care and critical infrastructure requirements.

Collaborative ventures are also on the rise, as major defense contractors join forces with academic research centers and emerging life science startups to co-develop platforms spanning sequencing-based surveillance to mRNA-based vaccine technologies. Mergers and acquisitions remain a catalyst for portfolio diversification, enabling companies to rapidly fill gaps in their countermeasure pipelines.

Meanwhile, a new wave of agile startups is carving out niches in specialized detection chemistries and compact distribution systems. These ventures often secure seed funding through innovation grants and engage in pilot deployments with local government entities to validate performance under real-world conditions.

Overall, the competitive landscape is being reshaped by an interconnected web of established players and nimble newcomers, each contributing to a more comprehensive and resilient biodefense capability set.

Actionable Strategic Recommendations to Enhance Resilience Agility and Collaborative Readiness Within the Biodefense Ecosystem

To fortify biodefense readiness and drive sustained innovation, organizations should adopt a multipronged strategy that emphasizes early detection, supply chain robustness, and collaborative intelligence. First, investment in advanced diagnostic platforms such as high-throughput sequencing and AI-powered biosensor networks will enable faster threat identification and more precise epidemiological tracking. Embedding these technologies within decentralized testing hubs can further amplify detection coverage and reduce response latency.

Second, supply chain strategies must shift from lean-only models to hybrid frameworks that incorporate redundant domestic and international manufacturing nodes. This dual approach not only mitigates the risk of single-source disruptions but also leverages the benefits of localized production incentives and specialized export controls. Establishing clear protocols for rapid scale-up of critical reagents and equipment will ensure that production ramp-up aligns with evolving threat levels.

Third, fostering sustained public-private partnerships and cross-disciplinary consortiums will accelerate the translation of research breakthroughs into field-ready solutions. Regular scenario-based exercises, joint training programs, and data-sharing agreements among defense agencies, health authorities, and commercial entities will enhance collective preparedness and illuminate latent capability gaps.

Fourth, harnessing the power of data analytics to integrate surveillance data, procurement trends, and regulatory updates will support more informed decision making. Deploying centralized dashboards and interoperable information systems across stakeholder groups will facilitate real-time visibility into critical supply metrics and evolving threat signatures.

Finally, proactive engagement with regulatory authorities to align on adaptive approval pathways and emergency use authorizations will streamline deployment of novel countermeasures. By combining these strategic pillars, industry leaders can elevate resilience, agility, and anticipatory governance across the biodefense ecosystem.

Detailed Research Methodology Integrating Data Collection Expert Consultations and Rigorous Analytical Frameworks for Biodefense Market Insights

Our analysis relies on a comprehensive research framework that integrates both primary insights from industry experts and rigorous secondary data collection. Initial secondary research involved a systematic review of peer-reviewed publications, government white papers, regulatory filings, and patent databases to identify foundational trends and emerging technologies. These insights were then supplemented by detailed company profiles and financial disclosures to map out current competitive dynamics and investment flows.

In parallel, more than fifty hours of in-depth interviews were conducted with key opinion leaders, including senior executives from government agencies, defense integrators, academic researchers, and technology providers. These discussions were structured to validate secondary findings, uncover nuanced market drivers, and assess the practical efficacy of recently deployed solutions. A structured questionnaire was used to ensure consistency in data collection across stakeholder segments.

Quantitative validation was achieved through data triangulation, aligning input from primary sources with secondary indicators such as procurement announcements, public funding allocations, and clinical trial registries. This multilayered approach enhances the reliability of insights and reflects the dynamic interplay between innovation cycles and regulatory shifts.

To ensure methodological rigor, all data points underwent cross-verification by an independent research team. Potential limitations, including data lags and proprietary information gaps, were addressed through sensitivity analysis and scenario modeling. The result is a robust intelligence foundation designed to inform strategic planning, technology roadmapping, and policymaking in the biodefense domain.

Concluding Perspectives on Future Trajectories Prioritization of Preparedness and Emerging Innovations in the Global Biodefense Arena

As the global threat landscape continues to evolve, the imperative for cohesive and agile biodefense strategies has never been more apparent. The convergence of technological strides, shifting trade policies, and dynamic regional priorities demands a comprehensive approach that bridges detection, prevention, and response. Organizations that successfully integrate advanced diagnostic platforms with resilient supply chain models and adaptive regulatory pathways will be best positioned to counter both known and emergent biological risks.

Looking ahead, the trajectory of biodefense will be characterized by deeper integration of artificial intelligence, decentralized surveillance networks, and modular manufacturing capabilities. These innovations will require not only capital investment but also the cultivation of interdisciplinary talent pools and collaborative frameworks that transcend traditional sector boundaries.

Ultimately, the future of biodefense hinges on a balanced fusion of proactive threat mitigation and reactive response readiness. By harnessing the insights presented in this executive summary-ranging from transformative market shifts to actionable recommendations-stakeholders can refine their strategic playbooks and prioritize initiatives that deliver the greatest impact.

In closing, this synthesis underscores the essential role of ongoing collaboration, data-driven decision making, and regulatory alignment in forging a more resilient and adaptive biodefense ecosystem. It calls on leaders across government, industry, and research institutions to seize the strategic imperatives outlined herein and drive forward a collective commitment to safeguarding public health and national security.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of AI-driven pathogen detection platforms for real-time biodefense monitoring
  • 5.2. Surge in synthetic biology investments accelerating rapid vaccine development pipelines
  • 5.3. Deployment of field-compatible mobile laboratories transforming on-site biodefense response readiness
  • 5.4. Integration of genomic surveillance networks into national biodefense early warning systems
  • 5.5. Escalating partnerships between defense agencies and biopharmaceutical firms for countermeasure R&D
  • 5.6. Shift towards CRISPR-based diagnostic assays enabling point-of-care detection of emerging threats
  • 5.7. Adoption of cloud-based bioinformatics platforms for global pathogen threat analysis and sharing
  • 5.8. Government-led funding initiatives driving expansion of high-containment biodefense facilities capacity
  • 5.9. Emergence of holistic supply chain resilience strategies to secure critical biodefense medical supplies
  • 5.10. Regulatory harmonization efforts streamlining emergency use approval processes for novel countermeasures

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Biodefense Market, by Product Type

  • 8.1. Introduction
  • 8.2. Decontamination Products
    • 8.2.1. Disinfectants
    • 8.2.2. PPE
  • 8.3. Detection Devices
    • 8.3.1. Biosensors
    • 8.3.2. Pathogen Detection Systems
  • 8.4. Therapeutics
    • 8.4.1. Antiviral Therapies
    • 8.4.2. Monoclonal Antibodies
  • 8.5. Vaccines
    • 8.5.1. Anthrax Vaccine
    • 8.5.2. Botulism Vaccine
    • 8.5.3. Smallpox Vaccine

9. Biodefense Market, by Pathogen Type

  • 9.1. Introduction
  • 9.2. Bacterial Agents
  • 9.3. Toxins
  • 9.4. Viral Agents

10. Biodefense Market, by Technology

  • 10.1. Introduction
  • 10.2. Immunoassays
  • 10.3. Mass Spectrometry
  • 10.4. Next Generation Sequencing
  • 10.5. Polymerase Chain Reaction

11. Biodefense Market, by Application

  • 11.1. Introduction
  • 11.2. Detection & Diagnostics
  • 11.3. Prevention
  • 11.4. Treatment

12. Biodefense Market, by End User

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Government & Defense Agencies
  • 12.4. Hospitals & Clinics
  • 12.5. Pharma & Biotech Companies

13. Biodefense Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Offline Channels
  • 13.3. Online Channels

14. Americas Biodefense Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Biodefense Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Biodefense Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Emergent BioSolutions Inc.
    • 17.3.2. Siga Technologies, Inc.
    • 17.3.3. Xoma Corporation
    • 17.3.4. Altimmune, Inc.
    • 17.3.5. Dynavax Technologies Corporation
    • 17.3.6. Elusys Therapeutics, Inc.
    • 17.3.7. Ichor Medical Systems
    • 17.3.8. DynPort Vaccine Company LLC
    • 17.3.9. Luminex Corporation
    • 17.3.10. Cleveland Biolabs Inc.
    • 17.3.11. Bavarian Nordic A/S
    • 17.3.12. Alnylam Pharmaceuticals, Inc.
    • 17.3.13. QIAGEN N.V.
    • 17.3.14. Ecolab Inc.
    • 17.3.15. Abbott Laboratories
    • 17.3.16. Bio-Rad Laboratories
    • 17.3.17. Nova Biomedical Corporation
    • 17.3.18. Siemens Healthcare
    • 17.3.19. Strados Labs
    • 17.3.20. Thermo Fisher Scientific
    • 17.3.21. Biofourmis Singapore Pte. Ltd.
    • 17.3.22. SD BIOSENSOR
    • 17.3.23. Lucentix SA

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. BIODEFENSE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL BIODEFENSE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. BIODEFENSE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. BIODEFENSE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. BIODEFENSE MARKET: RESEARCHAI
  • FIGURE 28. BIODEFENSE MARKET: RESEARCHSTATISTICS
  • FIGURE 29. BIODEFENSE MARKET: RESEARCHCONTACTS
  • FIGURE 30. BIODEFENSE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. BIODEFENSE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIODEFENSE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIODEFENSE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIODEFENSE MARKET SIZE, BY DISINFECTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIODEFENSE MARKET SIZE, BY DISINFECTANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIODEFENSE MARKET SIZE, BY PPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIODEFENSE MARKET SIZE, BY PPE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIODEFENSE MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIODEFENSE MARKET SIZE, BY BIOSENSORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN DETECTION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN DETECTION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIODEFENSE MARKET SIZE, BY ANTIVIRAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIODEFENSE MARKET SIZE, BY ANTIVIRAL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIODEFENSE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIODEFENSE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIODEFENSE MARKET SIZE, BY ANTHRAX VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIODEFENSE MARKET SIZE, BY ANTHRAX VACCINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIODEFENSE MARKET SIZE, BY BOTULISM VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIODEFENSE MARKET SIZE, BY BOTULISM VACCINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIODEFENSE MARKET SIZE, BY SMALLPOX VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIODEFENSE MARKET SIZE, BY SMALLPOX VACCINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIODEFENSE MARKET SIZE, BY BACTERIAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIODEFENSE MARKET SIZE, BY BACTERIAL AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIODEFENSE MARKET SIZE, BY TOXINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIODEFENSE MARKET SIZE, BY TOXINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIODEFENSE MARKET SIZE, BY VIRAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIODEFENSE MARKET SIZE, BY VIRAL AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIODEFENSE MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIODEFENSE MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIODEFENSE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIODEFENSE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIODEFENSE MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIODEFENSE MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION & DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION & DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIODEFENSE MARKET SIZE, BY PREVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIODEFENSE MARKET SIZE, BY PREVENTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIODEFENSE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIODEFENSE MARKET SIZE, BY TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIODEFENSE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIODEFENSE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIODEFENSE MARKET SIZE, BY GOVERNMENT & DEFENSE AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIODEFENSE MARKET SIZE, BY GOVERNMENT & DEFENSE AGENCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIODEFENSE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIODEFENSE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIODEFENSE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIODEFENSE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIODEFENSE MARKET SIZE, BY OFFLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIODEFENSE MARKET SIZE, BY OFFLINE CHANNELS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIODEFENSE MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIODEFENSE MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 151. MEXICO BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. MEXICO BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 199. ARGENTINA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 200. ARGENTINA BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 201. ARGENTINA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. ARGENTINA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 253. GERMANY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. GERMANY BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 257. GERMANY BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 259. GERMANY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 261. GERMANY BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 262. GERMANY BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 263. GERMANY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GERMANY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. GERMANY BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. GERMANY BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 267. GERMANY BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. GERMANY BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. GERMANY BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. GERMANY BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. GERMANY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 273. FRANCE BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. FRANCE BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. FRANCE BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 276. FRANCE BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 277. FRANCE BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 278. FRANCE BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 279. FRANCE BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 280. FRANCE BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 281. FRANCE BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 282. FRANCE BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 283. FRANCE BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. FRANCE BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 285. FRANCE BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. FRANCE BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 287. FRANCE BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. FRANCE BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 289. FRANCE BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. FRANCE BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 291. FRANCE BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 293. RUSSIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. RUSSIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. RUSSIA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 296. RUSSIA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 297. RUSSIA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 298. RUSSIA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 299. RUSSIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 300. RUSSIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 301. RUSSIA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 302. RUSSIA BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 303. RUSSIA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. RUSSIA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 305. RUSSIA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 307. RUSSIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. RUSSIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 309. RUSSIA BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. RUSSIA BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 311. RUSSIA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 313. ITALY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. ITALY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 315. ITALY BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 316. ITALY BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 317. ITALY BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 318. ITALY BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 319. ITALY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 321. ITALY BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 322. ITALY BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 323. ITALY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. ITALY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 325. ITALY BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. ITALY BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 327. ITALY BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. ITALY BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 329. ITALY BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. ITALY BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 331. ITALY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. ITALY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 333. SPAIN BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. SPAIN BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 335. SPAIN BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 336. SPAIN BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 337. SPAIN BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 338. SPAIN BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 339. SPAIN BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 340. SPAIN BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 341. SPAIN BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 342. SPAIN BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 343. SPAIN BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. SPAIN BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 345. SPAIN BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 346. SPAIN BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 347. SPAIN BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 348. SPAIN BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 349. SPAIN BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 350. SPAIN BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 351. SPAIN BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. SPAIN BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 353. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 354. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 355. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 365. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 367. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 368. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)

TAB